Breast cancer clinical trials

Explore recruiting breast cancer clinical trials.

Recruiting breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER)

Portugal, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Hungary, Germany, Austria, Spain, Netherlands, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study (COGNITION-GUIDE)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women

Poland, France, Italy, Greece, Spain, Ireland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Belgium, Spain, Hungary, Poland, Czechia, Portugal +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Breast cancer trials by city

Breast cancer in Toronto Breast cancer in Vancouver Breast cancer in Montreal Breast cancer in Calgary Breast cancer in Edmonton Breast cancer in Ottawa Breast cancer in Winnipeg Breast cancer in Quebec City Breast cancer in Hamilton Breast cancer in Kitchener Breast cancer in London Breast cancer in Halifax Breast cancer in New York Breast cancer in Los Angeles Breast cancer in Chicago Breast cancer in Houston

Breast cancer clinical trials

Recruiting breast cancer studies right now

Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

FAST-FORWARD vs HAI5

Preoperative Radiation Therapy and Immediate Breast Reconstruction

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2

Also recruiting in Europe

A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER)

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study (COGNITION-GUIDE)

OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women

Breast cancer trials by city

Other conditions